Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
María Asunción Esteve-PastorJosé Miguel Rivera-CaravacaVanessa RoldánMarcelo Sanmartín FernándezFernando ArribasJaime MasjuanVivencio BarriosJuan Cosin-SalesRomán Freixa-PamiasEsther RecaldeAlejandro I Pérez-CabezaJosé Manuel Vázquez RodríguezCarles Ráfols PriuManuel Anguita SánchezGregory Y H LipFrancisco MarínPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
In a prospective real-world AF population under rivaroxaban from EMIR registry, the HAS-BLED score had good predictive performance and calibration compared to ORBIT score for major bleeding events. ORBIT score presented worse calibration than HAS-BLED in this DOAC treated population.